title: Acinetobacter baumannii infection inhibits airway eosinophilia and lung pathology in a mouse model of allergic asthma.
abstract: Allergic asthma is a dysregulation of the immune system which leads to the development of Th2 responses to innocuous antigens (allergens). Some infections and microbial components can re-direct the immune response toward the Th1 response, or induce regulatory T cells to suppress the Th2 response, thereby inhibiting the development of allergic asthma. Since Acinetobacter baumannii infection can modulate lung cellular and cytokine responses, we studied the effect of A. baumannii in modulating airway eosinophilia in a mouse model of allergic asthma. Ovalbumin (OVA)-sensitized mice were treated with live A. baumannii or phosphate buffered saline (PBS), then intranasally challenged with OVA. Compared to PBS, A. baumannii treatment significantly reduced pulmonary Th2 cytokine and chemokine responses to OVA challenge. More importantly, the airway inflammation in A. baumannii-treated mice was strongly suppressed, as seen by the significant reduction of the proportion and the total number of eosinophils in the bronchoalveolar lavage fluid. In addition, A. baumannii-treated mice diminished lung mucus overproduction and pathology. However, A. baumannii treatment did not significantly alter systemic immune responses to OVA. Serum OVA-specific IgE, IgG1 and IgG2a levels were comparable between A. baumannii- and PBS-treated mice, and tracheobronchial lymph node cells from both treatment groups produced similar levels of Th1 and Th2 cytokines in response to in vitro OVA stimulation. Moreover, it appears that TLR-4 and IFN-γ were not directly involved in the A. baumannii-induced suppression of airway eosinophilia. Our results suggest that A. baumannii inhibits allergic airway inflammation by direct suppression of local pulmonary Th2 cytokine responses to the allergen.
authors.affiliation: Institute for Biological Sciences, National Research Council Canada, Ottawa, Ontario, Canada.
authors.forename: Hongyu
authors.initials: H
authors.lastname: Qiu
authors.forename: Rhonda
authors.initials: R
authors.lastname: Kuolee
authors.forename: Greg
authors.initials: G
authors.lastname: Harris
authors.forename: Hongyan
authors.initials: H
authors.lastname: Zhou
authors.forename: Harvey
authors.initials: H
authors.lastname: Miller
authors.forename: Girishchandra B
authors.initials: GB
authors.lastname: Patel
authors.forename: Wangxue
authors.initials: W
authors.lastname: Chen
mesh_terms: D000151:Acinetobacter Infections / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000276:immunology*; D000281:Administration, Intranasal; D000818:Animals; D001249:Asthma / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000382:microbiology*; D018925:Chemokines / Q000276:immunology; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000382:microbiology / Q000473:pathology*; D005260:Female; D007114:Immunization; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000378:metabolism; D008168:Lung / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D050296:Microbial Viability; D010047:Ovalbumin / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000378:metabolism
chemical_list: D018925:Chemokines; D007074:Immunoglobulin G; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D007073:Immunoglobulin E; D007371:Interferon-gamma; D010047:Ovalbumin